

# Assessing the Incidence Rate of Neuropsychiatric Adverse Effects in Older Adults Following Levetiracetam Initiation: A Retrospective Study

Mazen A Basheikh <sup>1,2</sup>

<sup>1</sup>Department of Internal Medicine, Faculty of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia; <sup>2</sup>Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

Correspondence: Mazen A Basheikh, Department of Medicine, Faculty of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia, Tel +966504325067, Email mabasheikh@uj.edu.sa

**Background:** Levetiracetam (LEV) is commonly prescribed for epilepsy management. However, neuropsychiatric disorders (NPDs) are concerning adverse effects that may result in medication discontinuation. This study aims to examine the incidence and factors influencing LEV associated NPDs in adult patients aged 50 years and above.

**Methods:** A retrospective analysis was conducted on patients aged 50 years and above prescribed LEV between 2010 and 2020, with at least one follow-up appointment six months post-treatment initiation. The incidence of new-onset or aggravated NPDs and variables potentially influencing this risk were examined. Independent *t*-test, chi-squared, and Fisher's exact test were used, in addition to univariate and multivariate logistic regression.

**Results:** The study included 100 patients with a mean age at LEV start of 63.31 years (SD = 16.48). Neuropsychiatric symptoms were observed in 6 (6.0%) patients. Factors associated with new-onset NPDs were younger age at epilepsy diagnosis ( $p=0.005$ ), younger age at LEV start ( $p=0.004$ ), and concurrent use of Carbamazepine/Oxcarbazepine ( $p=0.004$ ). On multivariate analysis, only the association with Carbamazepine/Oxcarbazepine remained significant (OR 14.62, 95% CI 1.86–114.70,  $p=0.011$ ).

**Conclusion:** The findings indicate that the incidence of NPDs in elderly patients is relatively low (6%). Further research with larger samples is needed in comparison with a younger sample as a control group to confirm these findings.

**Keywords:** levetiracetam, neuropsychiatric disorders, elderly patients

## Introduction

Epilepsy is a common neurological disorder characterized by a sustained propensity to generate epileptic seizures, leading to a spectrum of cognitive, psychological, and social repercussions. It manifests with transient motor (the most frequent), sensory, sensitive, autonomic, or cognitive symptoms originating from abnormal excessive or synchronous neuronal activity within the brain that results from an imbalance between excitation and inhibition of neuronal circuits.<sup>1</sup> According to the WHO, it is estimated that 5 million people are diagnosed with epilepsy every year worldwide, with about 80% of epileptic patients living in low- and middle-income countries.<sup>2</sup> Nonetheless, the availability of effective antiseizure agents considerably reduced the burden of this disorder, as over 70% of the affected individuals can live seizure-free if properly diagnosed and treated.<sup>2</sup>

Levetiracetam (LEV), a pyrrolidone derivative developed from piracetam, is among the first-line medications for epilepsy. It has demonstrated tolerability and effectiveness against both focal and generalized seizures in children and adults.<sup>3,4</sup> The pharmacological effects of LEV are attributed to its modulation of neuronal activity through various mechanisms. It binds to the synaptic vesicle protein 2A (SV2A), a glycoprotein essential for presynaptic neurotransmission present mainly in the cortex, thalamus, basal ganglia, and hippocampus, leading to a decreased seizure threshold in epileptogenic brain areas.<sup>5</sup> Furthermore, LEV has additional potential antiseizure effects. It increases the levels of the inhibitory neurotransmitter GABA and neurosteroids such as allopregnanolone, while decreasing excitatory glutamate. It also modulates serotonergic,  $\alpha_2$ -adrenergic, and  $\mu$ -opioid receptor-mediated signaling, and reduces intraneuronal calcium levels.<sup>6,7</sup>

However, these effects of LEV can result in secondary interference with other neurological functions such as mood and behavior regulation, ultimately leading to neuropsychiatric disorders (NPDs).<sup>6</sup> A case–control study involving 841 patients with a mean age of 44.7 years old showed that LEV therapy was independently associated with greater frequency of anger/aggression, nervousness/agitation, depression, and sleep disturbance, compared to other treatments.<sup>8</sup> In another large case–control study of 4085 epilepsy patients (mean age: 41 years), LEV displayed the highest rates of psychiatric adverse events compared to the other antiseizure medications (ASMs). These effects resulted in higher intolerability rate of 17.7%, a dose reduction rate of 9.8% and complete cessation rate of 8.3%.<sup>3</sup> Moreover, previous systematic reviews of safety revealed that following LEV therapy, the incidence of somnolence was 14.8%, dizziness 8.8%, depression 4%, nervousness 3.9%, insomnia 3.1%, hostility 2.3%, anxiety 1.8% and emotional lability 1.7%.<sup>9,10</sup>

ASMs are commonly prescribed drugs for the elderly population, as they are particularly susceptible to new-onset epilepsy, often symptomatic and a consequence of epilepsy-causing geriatric conditions such as stroke and Alzheimer's disease.<sup>11</sup> Furthermore, aging is a known factor that influences the pharmacokinetics and pharmacodynamics of drugs, which may favor the development of ASMs-related side effects including mental disorders.<sup>12</sup> Another significant concern is that LEV-associated NPDs can range in severity and, in some cases, lead to either discontinuation of LEV or the initiation of psychotropic medications.<sup>13</sup> However, the incidence of LEV-induced NPDs in the elderly population remains insufficiently explored. In response to this gap, we conducted the present research to determine the frequency and factors of these reactions in geriatric patients, aiming to enhance medication safety and adherence for this demographic.

## Aim & Objectives

The aim of this study is to evaluate the neuropsychiatric side effects of LEV in an elderly population. This assessment serves to not only quantify the risk of new or exacerbated NPDs associated with LEV use but also to determine potential factors that might influence this risk. The following objectives were explored:

- To estimate the incidence risk of new-onset or aggravated neuropsychiatric adverse effects associated with LEV among older adults.
- To identify potential factors influencing the risk of these adverse effects.
- To assess the efficacy of LEV in managing seizures in older adults.

These findings could contribute to refining prescribing practices, enhancing patient safety and potentially improving the quality of life for older adults dealing with seizure disorders. It could serve to guide physicians in making informed decisions when initiating LEV in this specific population, being fully aware of its potential benefits and drawbacks.

## Methods

### Study Design and Setting

This study was designed as a retrospective analysis, carried out at the outpatient Department of King AbdulAziz University Hospital (KAUH), Jeddah, Saudi Arabia.

### Participants

The study population comprised adults aged 50 years and above who had been prescribed LEV between the years 2010 and 2020. For inclusion in the study, participants had to have at least one follow-up appointment attended six months or more after the initiation of the LEV treatment.

### Sampling

We used a random sampling method for this study, which involves selecting individuals from the pool of patients aged 50 years and above, visiting the outpatient clinic department at KAUH. The targeted participants for our sample are individuals aged 50 years and above who have been diagnosed with epilepsy or seizures and either previously prescribed LEV and are still taking it or have started taking LEV after their first visit.

## Data Collection

The collection of necessary data elements was undertaken meticulously from the medical records available at King AbdulAziz University Hospital. This data encompassed demographics such as age, gender, and weight, as well as specific medical details. The latter included past medical history, particularly stroke, dementia, and psychiatric disorders, and medication history focusing on the use of ASMs. Further detailed data were collected regarding the pattern of LEV prescription. This involved the age at which treatment commenced, frequency and dosage of LEV, duration of treatment, and presence of any associated ASMs. Data specific to the medication's efficacy, such as the incidence of seizures post-treatment, were also recorded. Finally, we identified and recorded any occurrence of new-onset or aggravated neuropsychiatric adverse effects.

In the interest of protecting patient privacy, all personal identifying information was omitted from the collected data, thus maintaining patient anonymity throughout the study.

## Data Analysis

All data, once collected and coded, were analyzed using the Statistical Package for Social Sciences (SPSS) software, version 21 for Windows. Categorical variables were represented in terms of percentages, while the distributions of continuous variables were presented as means and standard deviations. The Independent *t*-test was utilized to compare the means of two independent groups for normally distributed data. The Chi-square test was employed for comparing categorical variables, and Fisher's exact test was utilized when the expected count in any cell of a contingency table was below 5. Additionally, univariate and multivariate logistic regression analyses were conducted to analyze factors associated with new-onset NPDs among the subjects. The univariate logistic regression was performed to explore the relationship between each independent variable and the dependent variable separately, while multivariate logistic regression was applied to identify the independent factors associated with NPDs, adjusting for possible confounders. All tests were two-tailed, and a *p*-value less than 0.05 was considered statistically significant.

## Ethical Clearance

This study was conducted with strict adherence to ethical considerations to ensure the protection and respect of the patients involved. Confidentiality and privacy were prioritized throughout the data collection and analysis process. The patient data utilized in this retrospective study were anonymized and de-identified before use, to protect the patients' identities and sensitive information. The research protocol was reviewed and approved by the Institutional Review Board at King AbdulAziz University Hospital, and it was carried out in accordance with the Declaration of Helsinki and its later amendments or comparable ethical standards. Furthermore, as this study involved a review of past patient records, informed consent was not directly obtained from the patients; however, all data were handled with the utmost care to preserve confidentiality and privacy.

## Results

### Baseline Characteristics and Outcome

We included 100 patients, 55 of them were male, and the mean age was 63.31 (range 50–97) years. Medical history showed a high prevalence of stroke (60%), while psychiatric history showed dementia (9.0%) and other psychiatric disorders (7.0%), and 10 of the participants were taking psychiatric drugs. New-onset neuropsychiatric symptoms were recorded in 6 (6.0%) patients. No worsening of previously reported psychiatric symptoms was identified in this sample (Table 1). Thus, the incidence of neuropsychiatric adverse effects was estimated as 6% (95% CI: 2.2–12.6%).

### Patterns of LEV Prescribing

The majority (98%) received the drug twice daily (BID). The most commonly prescribed LEV dosage was 500 mg (55.0%), followed by 1000 mg (17.0%) per dose. All patients continued the drug for at least six months. The use of associated ASMs

**Table 1** Baseline Characteristics and Outcomes

Parameter	Mean	SD
Age at epilepsy diagnosis, in years	59.68	20.93
Weight (kg)	74.01	16.16
Parameter	N	%
Gender		
Male	55	55.0
Female	45	45.0
Medical history		
Stroke	60	60.0
Dementia	9	9.0
Psychiatric disorder	7	7.0
Psychiatric drugs	10	0.0
Other antiseizure drugs		
Phenytoin	25	30.0
Valproic acid	10	10.0
Carbamazepine / Oxcarbazepine	15	15.0
Topiramate	6	6.0
Lamotrigine	7	7.0
Others	20	20.0
Outcomes		
New-onset neuropsychiatric symptom	6	6.0

was prevalent, with phenytoin being the most common (25.0%), followed by “Others” category drugs (17.0%) and Carbamazepine/Oxcarbazepine (15.0%). The majority of these drugs were prescribed before the patient was seen in the neurology clinic and then started on LEV. Majority of the patients were prescribed with only one associated ASM (61.0%). Treatment efficacy showed that 38% of the patients became seizure-free, while 19% were partially improved. However, data were missing or patients were lost to follow-up in 34% of the cases. Please refer to [Table 2](#) for a detailed breakdown of the data.

## Factors Associated with NPDs

Factors associated with new-onset NPDs among patients on LEV treatment were examined in [Table 3](#). The younger age at diagnosis and LEV start were significantly associated with NPDs, with mean ages at diagnosis being 61.21 years for patients without NPD and 37.00 years for those with NPDs ( $p=0.005^*$ ), and mean ages at LEV start being 64.53 years and 45.00 years, respectively ( $p=0.004^*$ ). Although not statistically significant, the prevalence of NPDs was higher in females (11.1%) than males (1.8%), and in those with a psychiatric disease history (28.6%) compared to those without (4.3%). The use of a maximum dose of 1000 g or higher of LEV was associated with a higher incidence of NPDs (12.5%) compared to those on a lower dose (2.9%), but this difference was not statistically significant. On the other hand, the concurrent use of Carbamazepine/Oxcarbazepine was significantly associated with the occurrence of NPDs (26.7% vs 2.4%,  $p=0.004^*$ ). Additionally, associated Lamotrigine use showed a higher prevalence of new-onset NPDs, with 28.6% among users versus 4.3% among non-users, though this difference was not statistically significant ( $p=0.055$ ).

**Table 2** Patterns of Levetiracetam Prescribing (N=100)

Parameter	Level	Statistics	
		Mean, SD	Median, range
Age at start of LEV (years)		63.31	16.48
		65.5	4, 92
Parameter	Level	Frequency	Percentage
Frequency	OD	2	2.0
	BID	98	98.0
Maximum dose (mg) per dose	250	4	4.0
	500	55	55.0
	750	9	9.0
	1000	17	17.0
	1500	7	7.0
	2000	8	8.0
Drug continued at least 6 months	Yes	100	100.0
Associated ASMs	Phenytoin	25	25.0
	Valproic acid	10	10.0
	Carbamazepine / Oxcarbazepine	15	15.0
	Topiramate	6	6.0
	Lamotrigine	7	7.0
	Lacosamide	3	3.0
	Others	17	17.0
Number of combined antiseizure medications	0 (LEV alone)	28	28.0
	1	61	61.0
	2	10	10.0
	3	1	1.0
Treatment efficacy	Seizure free	38	38.0
	Partially improved	19	19.0
	No improvement	4	4.0
	Deceased	5	5.0
	No data or lost followup	34	34.0

**Abbreviation:** LEV, levetiracetam.

Interestingly, no cases of new-onset NPDs were reported among patients who had complete therapeutic response (seizure-free). Please refer to [Table 3](#) for more detailed information.

## Predictors of NPDs

[Table 4](#) delineates the independent factors associated with new-onset NPDs. Univariate analysis revealed that the age at diagnosis (Odds Ratio (OR) 0.96, 95% Confidence Interval (CI) 0.93–0.99,  $p=0.014^*$ ) and age at LEV start (OR 0.95, 95% CI 0.92–0.99,  $p=0.012^*$ ) were significantly associated with decreased risk of these disorders. Additionally, the concurrent use of Carbamazepine/Oxcarbazepine increased the risk considerably (OR 15.09, 95% CI 2.47–92.23,  $p=0.003^*$ ). However, upon multivariate adjustment, only the association with Carbamazepine/Oxcarbazepine remained significant (OR 14.62, 95% CI 1.86–114.70,  $p=0.011^*$ ), indicating it as an independent risk factor for new-onset NPDs in patients on LEV. For more detailed data, refer to [Table 4](#).

**Table 3** Factors Associated with New-Onset Neuropsychiatric Disorders

Factor	Level	New-Onset or Aggravated NPDs				p-value
		No (n=94)		Yes (n=6)		
		Mean	SD	Mean	SD	
Age at diagnosis	(years)	61.21	19.76	37.00	26.46	0.005 <sup>*,a</sup>
Age at LEV start	(years)	64.53	15.45	45.00	22.12	0.004 <sup>*,a</sup>
		<b>N</b>	<b>%</b>	<b>N</b>	<b>%</b>	
Gender	Male	54	98.2	1	1.8	0.088
	Female	40	88.9	5	11.1	
Stroke history	No	39	97.5	1	2.5	0.397
	Yes	55	91.7	5	8.3	
Dementia	No	85	93.4	6	6.6	1.000
	Yes	9	100.0	0	0.0	
Psychiatric disease	No	89	95.7	4	4.3	0.055
	Yes	5	71.4	2	28.6	
Maximum dose	<1000 g	66	97.1	2	2.9	0.081
	≥1000 g	28	87.5	4	12.5	
Phenytoin	No	64	91.4	6	8.6	0.174
	Yes	30	100.0	0	0.0	
Valproic acid	No	79	92.9	6	7.1	0.587
	Yes	15	100.0	0	0.0	
Carbamazepine / Oxcarbazepine	No	86	95.6	4	4.4	0.109
	Yes	8	80.0	2	20.0	
Topiramate	No	93	93.9	6	6.1	1.000
	Yes	1	100.0	0	0.0	
Lamotrigine	No	93	93.9	6	6.1	1.000
	Yes	1	100.0	0	0	
Others	No	92	93.9	6	6.1	1.000
	Yes	2	100.0	0	0.0	
Associated Phenytoin	No	68	91.9	6	8.1	0.335
	Yes	26	100.0	0	0.0	
Associated Valproic acid	No	84	93.3	6	6.7	1.000
	Yes	10	100.0	0	0.0	
Associated Carbamazepine / Oxcarbazepine	No	83	97.6	2	2.4	0.004 <sup>*</sup>
	Yes	11	73.3	4	26.7	
Associated Topiramate	No	88	93.6	6	6.4	1.000
	Yes	6	100.0	0	0.0	
Associated Lamotrigine	No	89	95.7	4	4.3	0.055
	Yes	5	71.4	2	28.6	
Associated Lacosamide	No	92	94.8	5	5.2	0.171
	Yes	2	66.7	1	33.3	

(Continued)

**Table 3** (Continued).

Factor	Level	New-Onset or Aggravated NPDs				p-value
		No (n=94)		Yes (n=6)		
		Mean	SD	Mean	SD	
Other associated ASM	No	77	92.8	6	7.2	0.586
	Yes	17	100.0	0	0.0	
No. associated ASMs	0	27	96.4	1	3.6	0.266 <sup>b</sup>
	1	58	95.1	3	4.9	
	2	8	80.0	2	20.0	
	3	1	100.0	0	0.0	
Treatment efficacy	Seizure-free	38	100.0	0.0	0.0	0.122 <sup>b</sup>
	Partially improved	16	84.2	3	15.8	
	No improvement	2	66.7	1	33.3	
	Deceased	5	100.0	0	0.0	
	Discontinuation	1	100.0	0	0.0	
	Seizure-free on other ASM	1	100.0	0	0.0	
	No data or follow up	31	93.9	2	6.1	

**Notes:** \*Statistically significant result ( $p < 0.05$ ). Test used: <sup>a</sup>independent t-test; <sup>b</sup>chi square test; otherwise, Fisher's exact test was used. Noting that complete therapeutic response (seizure-free) was associated with no case of new-onset neuropsychiatric disorder.

**Abbreviations:** NPDs, neuropsychiatric disorders; ASMs, antiseizure medications.

**Table 4** Independent Factors Associated with New-Onset Neuropsychiatric Disorders Among Patients on Levetiracetam

Predictor / Level	Univariate				Multivariate			
	OR	95% CI		p-value	OR	95% CI		p-value
Age at diagnosis (years)	0.96	0.93	0.99	0.014*	1.01	0.94	1.09	0.775
Age at LEV start	0.95	0.92	0.99	0.012*	0.94	0.86	1.04	0.226
Associated Carbamazepine / Oxcarbazepine	15.09	2.47	92.23	0.003*	14.62	1.86	114.70	0.011*

**Note:** \*Statistically significant result ( $p < 0.05$ ).

**Abbreviations:** OR, Odds ratio; 95% CI, 95% confidence interval.

## Discussion

### Summary of Findings

This retrospective study of 100 older adult patients examined the neuropsychiatric side effects of LEV in the elderly. The risk of new-onset or aggravated neuropsychiatric adverse effects linked to LEV was estimated at 6.0%. We identified several factors influencing the risk of such adverse effects. Younger age at epilepsy diagnosis and LEV initiation were significantly associated with the onset of NPDs. Additionally, concurrent use of Carbamazepine/Oxcarbazepine was found to be an independent risk factor for the onset of such disorders in patients on LEV, even after adjusting for possible confounders. In terms of LEV's efficacy in managing seizures, 38% of the patients became seizure-free, while 19% were partially improved. However, a significant number of patients were either lost to follow-up or data were missing, making it challenging to draw a definitive conclusion about LEV's efficacy in seizure management.

### Incidence Risk of Neuropsychiatric Adverse Effects

In this study, we observed a 6% incidence of LEV-induced NPDs in elderly epileptic patients. While this rate cannot be directly compared to other studies due to a lack of data specific to the geriatric population, it is lower than reported rates in

younger cohorts. For instance, a study by Josephson et al reported a higher NPD incidence, with 14.1% of 1173 adults (median age: 39) manifesting psychiatric symptoms or disorders over a 2-year prescription period. Notably, this study introduced two predictive models for LEV-induced psychiatric adverse events and validated their effectiveness.<sup>14</sup> Another study involving 568 epileptic patients (mean age: 33) found that using LEV, either as monotherapy or in combination, was associated with irritability in 24% of patients, dizziness in 20.1%, headache in 11.8%, somnolence in 11.6%, depression in 6.9%, and psychosis in 1.1% after a 29.3-month follow-up.<sup>15</sup> Such adverse events could significantly influence treatment discontinuation in the elderly, especially as LEV's tolerability is known to decrease with age.<sup>16</sup>

## The Influence of Patient Age at Diagnosis and LEV Start on NPDs

We identified a positive correlation of the emergence of NPDs with an earlier diagnosis of epilepsy and LEV initiation. Both factors indicate a prolonged duration of LEV consumption, potentially leading to more pronounced disruptions in neuronal function. It is suggested that repeated LEV administration might exert a cumulative effect on neurons, heightening the risk for psychiatric manifestations.<sup>17</sup> Prolonged inhibition of certain neurotransmissions, such as glutamatergic and serotonergic, coupled with a chronic increase in GABA activity, might induce sustained alterations in cognition, behavior, and mood regulation. This theory aligns with evidence that LEV's inhibition of synaptic vesicle release is both stimulation- and time-dependent,<sup>18</sup> suggesting deeper neuronal interference after extended use. Additionally, patients with a long epilepsy history are more likely to be exposed to other ASMs that could disrupt CNS neurotransmission. When combined with LEV, these effects might be amplified, increasing the likelihood of NPD development.

## The Role of Concurrent Carbamazepine/Oxcarbazepine Use

Co-administration of LEV with the enzyme-inducing antiseizure drug Carbamazepine increases LEV clearance by 24–37%, thereby reducing its retention in the body.<sup>16</sup> Carbamazepine levels remained stable when LEV was introduced to patients with resistant epilepsy.<sup>19</sup> Similarly, Oxcarbazepine's potential to boost LEV retention appears minimal.<sup>20</sup> This indicates that the heightened LEV toxicity when combined with carbamazepine or oxcarbazepine stems from a pharmacodynamic interaction rather than a pharmacokinetic one.<sup>19</sup> ASM-induced psychiatric anomalies are believed to arise from the modulation of neurotransmitters like glutamate (through AMPA receptor inhibition) and serotonin, and the amplification of GABA-dependent signals, all of which influence behavior and mood regulation.<sup>6</sup> Given that LEV, carbamazepine, and oxcarbazepine all interact with these neurotransmitters in the CNS, their combined use could intensify mood and behavioral changes.<sup>6,21–23</sup>

## Efficacy of LEV in Managing Seizures

LEV is a primary treatment option for epilepsy and is particularly effective in elderly patients.<sup>24</sup> Besides its clinical safety and effectiveness,<sup>3,4</sup> fundamental research has shown that LEV has several mechanisms of action, such as binding to synaptic vesicle protein 2A (SV2A), enhancing inhibitory neurotransmitters like GABA, restoring brain levels of allopregnanolone, and reducing and modulating various excitatory and pro-epileptic neurotransmitters.<sup>5–7</sup> The American Academy of Neurology and the American Epilepsy Society advocates for LEV in managing adults with new-onset epilepsy, based on its proven efficacy in clinical trials.<sup>25</sup> In Phase III clinical trials, LEV, as an add-on therapy at doses between 1000 and 3000 mg/day, reduced seizure frequency in patients with partial-onset seizures.<sup>26–28</sup> While studies support LEV's utility in geriatric patients, comprehensive evidence is still emerging.<sup>29</sup> LEV has shown efficacy in elderly patients with cognitive impairment<sup>30</sup> and in reducing late-onset post-stroke seizures.<sup>31</sup> It also outperformed standard ASMs, Valproate and Carbamazepine, as an initial monotherapy for new-onset epilepsy in patients aged  $\geq 60$ , evidenced by longer treatment duration and better tolerability.<sup>32</sup> Enhancing LEV adherence in the elderly could be achieved by vigilant monitoring of side effects, including NPDs, to prevent treatment discontinuation.

## Strengths and Limitations

To the best of our knowledge, this is the inaugural study to delineate the frequency of new-onset neuropsychiatric adverse events in elderly epilepsy patients treated with LEV for a minimum of six months. The study involved decade-long



retrospective data, and identified significant factors correlated with NPDs, offering potential therapeutic insights. However, our research has some limitations. The first major limitation is the retrospective design, which is subject to information bias, including the absence of essential data and missing values for certain variables, thereby restricting the examination of outcomes and associated risk factors. The second notable limitation is a relatively small sample size, resulting in a high type 2 error, which limits the significance of certain statistical associations. The study also did not detail the specific types or severities of NPDs, nor their management strategies. An exploration into how these NPDs influenced patients' decisions to continue treatment would also have been valuable.

## Conclusion

While LEV is known to cause neuropsychiatric side effects, the incidence of these side effects seems to be lower in older adults. The concurrent prescription of LEV and carbamazepine/oxcarbazepine may contribute to the emergence of NPDs and warrants careful consideration in this age group. This suggests a cautious approach to using these drugs in combination. More extensive research with larger sample sizes would be valuable in further exploring this critical aspect of patient care. The findings from this study can contribute to refining prescribing practices, enhancing patient safety, and potentially improving the quality of life for older adults dealing with seizure disorders.

## Abbreviations

LEV, Levetiracetam; ASMs, antiseizure medications; NPDs, neuropsychiatric disorders.

## Acknowledgments

The author thanks Dr. Mohammed Basheikh and the company Scientia Vallis, Paris, represented by Dr. Mohamed Amine Haireche, for their support in the preparation of this manuscript. This paper has been uploaded to Heliyon as a preprint: [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=4647895](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4647895).

## Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Disclosure

The author reports no conflicts of interest in this work.

## References

1. Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. *Cold Spring Harb Perspect Med*. 2015;5. doi:10.1101/cshperspect.a022426
2. World Health Organization. (WHO) Epilepsy, Fact Sheets; n.d. Available from: <https://www.who.int/news-room/fact-sheets/detail/epilepsy#>. Accessed August 20, 2023.
3. Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. *Epilepsy Behav*. 2017;76:24–31. doi:10.1016/j.yebeh.2017.08.039
4. Abou-Khalil B. Levetiracetam in the treatment of epilepsy. *Neuropsychiatr Dis Treat*. 2008;4:507–523. doi:10.2147/ndt.s2937
5. Cortes-Altamirano JL, Olmos-Hernández A, Bonilla-Jaime H, Bandala C, González-Maciél A, Alfaro-Rodríguez A. Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug. *Neuro India*. 2016;64:1266–1275. doi:10.4103/0028-3886.193801
6. Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. *Behav Neurol*. 2018;2018:2064027. doi:10.1155/2018/2064027
7. Costa AM, Lucchi C, Malkoç A, Rustichelli C, Biagini G. Relationship between delta rhythm, seizure occurrence and allopregnanolone hippocampal levels in epileptic rats exposed to the rebound effect. *Pharmaceuticals*. 2021;14:127. doi:10.3390/ph14020127
8. Kowski AB, Weissinger F, Gaus V, Fidzinski P, Losch F, Holtkamp M. Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. *Epilepsy Behav*. 2016;54:150–157. doi:10.1016/j.yebeh.2015.11.009
9. Harden C. Safety Profile of Levetiracetam. *Epilepsia*. 2001;42:36–39. doi:10.1111/j.1528-1167.2001.00008.x
10. Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. *Epilepsy Behav*. 2003;4:124–132. doi:10.1016/s1525-5050(03)00005-2
11. Leppik IE, Birnbaum AK. Epilepsy in the elderly. *Ann N Y Acad Sci*. 2010;1184:208–224. doi:10.1111/j.1749-6632.2009.05113.x
12. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. *Br J Clin Pharmacol*. 2004;57:6–14. doi:10.1046/j.1365-2125.2003.02007.x
13. Tao K, Chen H, Chen Y, Gu Y, Wang X. Levetiracetam induces severe psychiatric symptoms in people with epilepsy. *Seizure*. 2022. doi:10.1016/j.seizure.2022.12.002

14. Josephson CB, Engbers JDT, Jette N, et al. Prediction tools for psychiatric adverse effects after levetiracetam prescription. *JAMA Neurol.* 2019;76:440–446. doi:10.1001/jamaneurol.2018.4561
15. Kang BS, Moon HJ, Kim Y-S, et al. The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre. *Epileptic Disord.* 2013;15:302–310. doi:10.1684/epd.2013.0599
16. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. *Epilepsia.* 2007;48:1351–1359. doi:10.1111/j.1528-1167.2007.01043.x
17. Özcan H, Ulkevan T, Ustundag MF, Yucel A. Levetiracetam-induced acute mania. *Klin Psikofarmakol Bul.* 2015;25:319–320. doi:10.5455/bcp.20150212042745
18. Yang X-F, Rothman SM. Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission. *Seizure.* 2009;18:615–619. doi:10.1016/j.seizure.2009.07.004
19. Sisodiya SM, Sander JWAS, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. *Epilepsy Res.* 2002;48:217–219. doi:10.1016/s0920-1211(01)00309-6
20. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. *Expert Rev Neurother.* 2010;10:119–140. doi:10.1586/ern.09.136
21. Waldmeier PC, Martin P, Stöcklin K, Portet C, Schmutz M. Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. *Naunyn Schmiedeberg Arch Pharmacol.* 1996;354:164–172. doi:10.1007/BF00178716
22. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine. *Neurosci Lett.* 2005;390:48–53. doi:10.1016/j.neulet.2005.07.049
23. Zheng T, Clarke AL, Morris MJ, Reid CA, Petrou S, O'Brien TJ. Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures. *Epilepsia.* 2009;50:83–87. doi:10.1111/j.1528-1167.2008.01759.x
24. Piccenna L, O'Dwyer R, Leppik I, et al. Management of epilepsy in older adults: a critical review by the ILAE Task Force on Epilepsy in the elderly. *Epilepsia.* 2023;64:567–585. doi:10.1111/epi.17426
25. Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology.* 2018;91:74–81. doi:10.1212/WNL.0000000000005755
26. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. *Neurology.* 2000;55:236–242. doi:10.1212/wnl.55.2.236
27. Shorvon SD, Löwenthal A, Janz D, Bielen E, Loiseau P; European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. *Epilepsia.* 2000;41:1179–1186. doi:10.1111/j.1528-1157.2000.tb00323.x
28. Ben-Menachem E, Falter U; European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. *Epilepsia.* 2000;41:1276–1283. doi:10.1111/j.1528-1157.2000.tb04605.x
29. Seo JG, Cho YW, Kim KT, et al. Pharmacological treatment of epilepsy in elderly patients. *J Clin Neurol.* 2020;16:556–561. doi:10.3988/jcn.2020.16.4.556
30. Lippa CF, Rosso A, Hepler M, Jenssen S, Pillai J, Irwin D. Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. *Am J Alzheimers Dis Other Dement.* 2010;25:149–154. doi:10.1177/1533317508325095
31. Kutlu G, Gomceli YB, Unal Y, Inan LE. Levetiracetam monotherapy for late poststroke seizures in the elderly. *Epilepsy Behav.* 2008;13:542–544. doi:10.1016/j.yebeh.2008.04.025
32. Pohlmann-Eden B, Marson AG, Noack-Rink M, et al. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. *BMC Neurol.* 2016;16:149. doi:10.1186/s12883-016-0663-7

International Journal of General Medicine

Dovepress

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>